| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/15/2001 | WO2001010440A1 COMPOSITIONS AND METHODS TO ENHANCE CANCER CHEMOTHERAPY IN p53 DEFECTIVE TUMORS |
| 02/15/2001 | WO2001010438A1 Anti-inflammatory actions of cytochrome p450 epoxygenase-derived eicosanoids |
| 02/15/2001 | WO2001010429A2 Long chain n-alkyl compounds and oxa-derivatives thereof and use as antiviral compositions |
| 02/15/2001 | WO2001010427A2 Use of anti-muscarinic agents for treating skin disorders |
| 02/15/2001 | WO2001010426A2 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer |
| 02/15/2001 | WO2001010425A2 Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes |
| 02/15/2001 | WO2001010423A2 Use of 5-ht3 receptor antagonists for the treatment of inflammations of the respiratory tract |
| 02/15/2001 | WO2001010411A2 Implantable active ingredient depot |
| 02/15/2001 | WO2001010387A2 Antiviral therapy use of p-glycoprotein modulators |
| 02/15/2001 | WO2001010381A2 Methods for treating or preventing pain and anxiety |
| 02/15/2001 | WO2001010323A1 Method of controlling body temperature while reducing shivering |
| 02/15/2001 | WO2000068687A3 Methods of identifying therapeutic compounds in a genetically defined setting |
| 02/15/2001 | WO2000066067A3 Ibd-associated microbial antigens and methods of using same |
| 02/15/2001 | WO2000065054A3 Human membrane-associated proteins |
| 02/15/2001 | WO2000064946A3 Compositions and methods for cancer treatment by selectively inhibiting vegf |
| 02/15/2001 | WO2000059490A3 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions |
| 02/15/2001 | WO2000058733A3 Assay for testing the efficacity of a therapy |
| 02/15/2001 | WO2000057900A3 Factor for regulation of neurite growth |
| 02/15/2001 | WO2000057852A3 Methods and compositions for treating solid tumors |
| 02/15/2001 | WO2000057721A3 Edible solids for treatment of glucose metabolism disorders |
| 02/15/2001 | WO2000053167A3 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
| 02/15/2001 | WO2000049144A3 Pyk2 binding proteins |
| 02/15/2001 | WO2000047198A3 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| 02/15/2001 | WO2000043419A3 Exocytosis pathway proteins and methods of use |
| 02/15/2001 | WO2000011204A3 Homer interacting proteins |
| 02/15/2001 | WO2000002549A8 Composition for and method of treating neurological disorders |
| 02/15/2001 | CA2382659A1 Dendritic enriched secreted lymphocyte activation molecule |
| 02/15/2001 | CA2381699A1 Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators |
| 02/15/2001 | CA2381284A1 Fhm, a novel member of the tnf ligand supergene family |
| 02/15/2001 | CA2380312A1 Formulations for parenteral use of estramustine phosphate and albumin |
| 02/15/2001 | CA2379608A1 Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| 02/15/2001 | CA2379052A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | CA2378984A1 Antiviral therapy use of p-glycoprotein modulators |
| 02/15/2001 | CA2378460A1 Peptides that block viral infectivity and methods of use thereof |
| 02/15/2001 | CA2378445A1 Use of anti-muscarinic agents for treating skin disorders |
| 02/15/2001 | CA2378401A1 Implantable active ingredient depot |
| 02/15/2001 | CA2378032A1 Crystallization and structure determination of staphylococcus aureus udp-n-acetylenolpyruvylglucosamine reductase (s. aureus murb) |
| 02/15/2001 | CA2376065A1 Crystallization and structure determination of staphylococcus aureus elongation factor p |
| 02/15/2001 | CA2374745A1 Proteases and protease inhibitors |
| 02/15/2001 | CA2346063A1 Composition and methods for treatment of hiv infection |
| 02/14/2001 | EP1075837A2 Process for the preparation of aqueous formulations for ophthalmic use |
| 02/14/2001 | EP1075535A1 A method for diagnosing and treating chronic pelvic pain syndrome |
| 02/14/2001 | EP1075528A1 Endothelin-converting-enzyme like protein |
| 02/14/2001 | EP1075518A2 Human transcriptional regulator molecules |
| 02/14/2001 | EP1075493A2 Dna encoding snorf25 receptor |
| 02/14/2001 | EP1075486A1 Method of treating bladder and lower urinary tract syndromes |
| 02/14/2001 | EP1075278A1 PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D 2?) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING $g(b) 2?-ADRENORECEPTOR AGONIST ACTIVITY |
| 02/14/2001 | EP1075277A2 Methods for detecting and inhibiting angiogenesis |
| 02/14/2001 | EP1075273A2 Inhibiton of helicobacter pylori proliferation |
| 02/14/2001 | EP1075272A1 Methods for treating diabetes by inhibiting gdf-8 |
| 02/14/2001 | EP1075271A2 Method of treating interstitial cystitis with recombinant heparin-binding epidermal growth factor-like growth factor (hb-egf) |
| 02/14/2001 | EP1075266A1 Hematopoietic stimulation |
| 02/14/2001 | EP1075255A1 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof |
| 02/14/2001 | EP0983380A4 Methods for treating bipolar mood disorder associated with markers on chromosome 18q |
| 02/14/2001 | EP0844874A4 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ALPHA v BETA 5 MEDIATED ANGIOGENESIS |
| 02/14/2001 | CN1284071A Sulphona mide derivatives as prodrugs of aspartyl protease inhibitors |
| 02/14/2001 | CN1284056A Anticonvulsant and sentral nervous system-active bis (fluorophenyl) alkylamides |
| 02/14/2001 | CN1283994A Methods for treatment of neuro-and nephro-disorders and therapeutic toxicities using aminothiol compounds |
| 02/14/2001 | CN1283990A Long cating injectable formulations contg. hydrogenated castor oil |
| 02/14/2001 | CN1283455A Application of black fading hormone and black fading ligand in medicinal compsns for prevention and treatment of gastrointestional tract disease |
| 02/14/2001 | CN1283451A Local compsn, contg, tocopherol |
| 02/13/2001 | US6187822 To inhibit adenosine diphosphate-ribosylation of vascular endothelial growth factor, wherein the enzyme inhibitor is selected from vitamin k1, vitamin k3, novobiocin, and silybin; healing wounds such as diaper dermatitis |
| 02/13/2001 | US6187819 Protein kinase C activators and their use in decreasing expression of cell antigens |
| 02/13/2001 | US6187817 Preventing or reducing ototoxicity in a human, cat or dog by administering d-methionine free of the l-isomer |
| 02/13/2001 | US6187815 Topically applying procaine and niacin in given dosage amount in a topical hydrophilic vehicle |
| 02/13/2001 | US6187814 By topically an farnesoid x-activated receptor (fxr) activator selected from farnesal, alkyl farnesyl ether, alkyl farnesoate, and 7-methyl-9-(3,3-dimethyloxiranyl)-3-methyl-2,6-nonadienoic acid, alkyl ester |
| 02/13/2001 | US6187811 Methods for treating benign prostatic hyperplasia using tocotrienols |
| 02/13/2001 | US6187806 N-linked sulfone of heterocyclic thioester hair growth compositions and uses |
| 02/13/2001 | US6187796 Alopecia treatment; immunophilin affinity |
| 02/13/2001 | US6187795 Methods and compositions for treating allergic disorders and other disorders using norastemizole in combination with other active ingredients |
| 02/13/2001 | US6187794 Administering as antiasthmatic agent; side effect reduction |
| 02/13/2001 | US6187784 Pipecolic acid derivative hair growth compositions and uses |
| 02/13/2001 | US6187752 Method for treating schizophrenia employing an ace inhibitor |
| 02/13/2001 | US6187745 Co-administration of a pentosan polysulfate (pps) or a pharmaceutically acceptable salt thereof. |
| 02/13/2001 | US6187562 Polynucleotides encoding human sphingosine Lyase |
| 02/13/2001 | US6187561 Nucleotide sequence coding enzymatic polypeptide associated with charging molecule during translation; for detection of bactericides; for antibiotic prophylaxis before dental treatment; for prevention of infections; wound healing agents |
| 02/13/2001 | US6187560 Nucleotide sequences coding mitochondrial polypeptide; for the treatment of dietetics, diabetes, hyperlipidemia and weight defects |
| 02/13/2001 | US6187542 Diagnosing humans with congestive heart failure; obtaining leukocyte sample, detecting mutation in gene coding hydrolase, the presence of mutation indicates sensitivity to congestive heart failure |
| 02/13/2001 | US6187338 Anticonvulsants and analgesics |
| 02/13/2001 | US6187304 Effects of IFN-γ on cardiac hypertrophy |
| 02/13/2001 | CA2146637C Pharmaceutical compositions and methods for treating cold symptoms |
| 02/09/2001 | CA2315594A1 Process for the preparation of aqueous formulations for ophthalmic use |
| 02/08/2001 | WO2001009612A1 Modulating binding site on potassium channels used for screening |
| 02/08/2001 | WO2001009390A1 Tenascin-c nucleic acid ligands |
| 02/08/2001 | WO2001009328A1 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof |
| 02/08/2001 | WO2001009189A2 Compositions and methods for the treatment of tumors |
| 02/08/2001 | WO2001009186A2 Therapeutic compounds comprised of anti-fc receptor binding agents |
| 02/08/2001 | WO2001009184A1 Human g-protein coupled receptor |
| 02/08/2001 | WO2001009183A2 Polymorphisms in the human mdr-1 gene and applications thereof |
| 02/08/2001 | WO2001009182A1 Prolactin-releasing peptide and method for regulating autonomic functions and treating pain |
| 02/08/2001 | WO2001009179A1 Moraxella cattarrhalis basb114 antigens and uses thereof |
| 02/08/2001 | WO2001009178A2 Human chaperone proteins |
| 02/08/2001 | WO2001009170A1 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (app) |
| 02/08/2001 | WO2001009140A1 Thienopyranecarboxamide derivatives |
| 02/08/2001 | WO2001009116A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 02/08/2001 | WO2001009114A1 Hiv integrase inhibitors |
| 02/08/2001 | WO2001009097A1 Cyclic amine derivatives for the treatment of neurological diseases |
| 02/08/2001 | WO2001008717A1 Controlled release implantable devices |
| 02/08/2001 | WO2001008708A2 Enhanced delivery via serpin enzyme complex receptor ligands |
| 02/08/2001 | WO2001008699A1 Methods of inhibiting osteoclastogenesis |